Primary Central Sleep Apnoea Syndrome: What to Do When Initial Pharmacological Treatment Has Not Worked

Patients with primary central sleep apnoea syndrome who remain symptomatic after a first-line pharmacological trial require escalation. This protocol defines the next structured step when initial therapy has failed its stated goals.

First-line failure condition

A prior trial of acetazolamide, zolpidem, or triazolam did not achieve the target goals: meaningful reduction in apnoea-hypopnoea index (AHI) and improvement in daytime sleepiness. Failure to meet these endpoints is the defined trigger for escalation to this protocol.

Next-line approach

For symptomatic patients in this situation, the protocol involves a trial of positive airway pressure therapy — the specific modality, criteria, and sequencing are detailed in the full structured regimen.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1183/20734735.0235-2023

Although zolpidem and triazolam demonstrated reductions in central AHI in patients with primary CSA syndrome, the underlying therapeutic mechanism is not answered.

Both CPAP and ASV can be considered in symptomatic patients.

View source ↗